Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 121 AL 135

Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration

Pac-Soo C, Lloyd DG, Vizcaychipi MP, Ma D.

J Alzheimers Dis. 2011;27(1):1-10. doi: 10.3233/JAD-2011-110524.

Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease

Wallace TL, Porter RH.

Biochem Pharmacol. 2011 Oct 15;82(8):891-903. doi: 10.1016/j.bcp.2011.06.034. Epub 2011 Jul 2.

The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats

Tramontina AC, Wartchow KM, Rodrigues L, Biasibetti R, Quincozes-Santos A, Bobermin L, Tramontina F, Gonçalves CA.

J Neural Transm (Vienna). 2011 Nov;118(11):1641-9. doi: 10.1007/s00702-011-0680-z. Epub 2011 Jul 10.

Rivastigmine associated hyponatremia in an older patient with Alzheimer's disease

Naharci IM, Bozoglu E, Karadurmus N, Karaman M, Kurt O, Doruk H.

J Am Geriatr Soc. 2011 Jul;59(7):1351-2. doi: 10.1111/j.1532-5415.2011.03468.x.

Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease

Parri HR, Hernandez CM, Dineley KT.

Biochem Pharmacol. 2011 Oct 15;82(8):931-42. doi: 10.1016/j.bcp.2011.06.039. Epub 2011 Jul 7.

Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial

Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A.

Lancet. 2011 Jul 30;378(9789):403-11. doi: 10.1016/S0140-6736(11)60830-1. Epub 2011 Jul 19.

Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies

Ha GT, Wong RK, Zhang Y.

Chem Biodivers. 2011 Jul;8(7):1189-204. doi: 10.1002/cbdv.201000269.

Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI

Goveas JS, Xie C, Ward BD, Wu Z, Li W, Franczak M, Jones JL, Antuono PG, Li SJ.

J Magn Reson Imaging. 2011 Oct;34(4):764-73. doi: 10.1002/jmri.22662. Epub 2011 Jul 18.

Cellular protection and therapeutic potential of tocotrienols

Catalgol B, Batirel S, Ozer NK.

Curr Pharm Des. 2011;17(21):2215-20. doi: 10.2174/138161211796957436.

Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease

Hampel H, Prvulovic D, Teipel SJ, Bokde AL.

Prog Neurobiol. 2011 Dec;95(4):570-8. doi: 10.1016/j.pneurobio.2011.05.012. Epub 2011 Jul 13.

[Dementia and dyslipidemia]

Tamaoka A.

Nihon Ronen Igakkai Zasshi. 2011;48(2):114-7. doi: 10.3143/geriatrics.48.114.

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup

Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ.

Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351.

The amyloid cascade hypothesis has misled the pharmaceutical industry

Biochem Soc Trans. 2011 Aug;39(4):920-3. doi: 10.1042/BST0390920.

Traditional Chinese medicines and Alzheimer's disease

Wu TY, Chen CP, Jinn TR.

Taiwan J Obstet Gynecol. 2011 Jun;50(2):131-5. doi: 10.1016/j.tjog.2011.04.004.

Fyn, a potential target for Alzheimer's disease

Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF, MacDonald JF.

J Alzheimers Dis. 2011;27(2):243-52. doi: 10.3233/JAD-2011-110353.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias